Rare diseases
Investigational molecules
Locations
345 conditions with trials, the busiest first
956 trials across Europe, recruiting first
Study of Pembrolizumab and Chemotherapy for Patients with HR+/HER2- Advanced Breast Cancer
AustriaStudy of Vobramitamab Duocarmazine and Prednisone for Patients with Metastatic Castration-Resistant Prostate Cancer
BelgiumStudy on the Effectiveness and Safety of OG-6219 and Naproxen Sodium for Women Aged 18-49 with Moderate to Severe Endometriosis Pain
BelgiumOpen‑Label Extension Study of Avutometinib Alone or with Defactinib in Patients with Recurrent Low‑Grade Serous Ovarian Cancer
FrancePreventing Heart Failure in Early Breast Cancer Patients Receiving Anthracycline Therapy with Sacubitril and Valsartan (LCZ696)
NorwayStudy of alpelisib with trastuzumab and pertuzumab as maintenance therapy in adult patients with HER2‑positive advanced breast cancer and PIK3CA mutation
FranceGedatolisib plus drug combination for HR‑positive, HER2‑negative advanced breast cancer patients whose disease progressed after CDK4/6 inhibitor therapy
AustriaA study to evaluate the safety and effectiveness of AZD9750 and saruparib in patients with metastatic prostate cancer
The NetherlandsSacituzumab Tirumotecan in Recurrent or Metastatic Cervical Cancer After Platinum Chemotherapy and Anti-PD-L1 or Anti-PD-1 Therapy
AustriaA study to compare how the body absorbs celecoxib oral suspension and celecoxib capsules in healthy adults for the treatment of acute pain.
CzechiaA Phase 3 Randomized Open-Label Study of Sacituzumab Govitecan Versus Physician's Choice in Recurrent or Persistent Endometrial Cancer Post-Chemotherapy and Immunotherapy
CzechiaBioavailability, Safety and Tolerability of elinzanetant (BAY 3427080) in Healthy Adults for Treatment of Vasomotor Symptoms
GermanyThe therapies tested most often in Reproductive system and breast disorders trials.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
